Cargando…

Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey

An online survey was conducted to compare the safety, tolerability and reactogenicity of available COVID-19 vaccines in different recipient groups. This survey was launched in February 2021 and ran for 11 days. Recipients of a first COVID-19 vaccine dose ≥7 days prior to survey completion were eligi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathioudakis, Alexander G., Ghrew, Murad, Ustianowski, Andrew, Ahmad, Shazaad, Borrow, Ray, Papavasileiou, Lida Pieretta, Petrakis, Dimitrios, Bakerly, Nawar Diar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002738/
https://www.ncbi.nlm.nih.gov/pubmed/33803014
http://dx.doi.org/10.3390/life11030249
_version_ 1783671533726597120
author Mathioudakis, Alexander G.
Ghrew, Murad
Ustianowski, Andrew
Ahmad, Shazaad
Borrow, Ray
Papavasileiou, Lida Pieretta
Petrakis, Dimitrios
Bakerly, Nawar Diar
author_facet Mathioudakis, Alexander G.
Ghrew, Murad
Ustianowski, Andrew
Ahmad, Shazaad
Borrow, Ray
Papavasileiou, Lida Pieretta
Petrakis, Dimitrios
Bakerly, Nawar Diar
author_sort Mathioudakis, Alexander G.
collection PubMed
description An online survey was conducted to compare the safety, tolerability and reactogenicity of available COVID-19 vaccines in different recipient groups. This survey was launched in February 2021 and ran for 11 days. Recipients of a first COVID-19 vaccine dose ≥7 days prior to survey completion were eligible. The incidence and severity of vaccination side effects were assessed. The survey was completed by 2002 respondents of whom 26.6% had a prior COVID-19 infection. A prior COVID-19 infection was associated with an increased risk of any side effect (risk ratio 1.08, 95% confidence intervals (1.05–1.11)), fever (2.24 (1.86–2.70)), breathlessness (2.05 (1.28–3.29)), flu-like illness (1.78 (1.51–2.10)), fatigue (1.34 (1.20–1.49)) and local reactions (1.10 (1.06–1.15)). It was also associated with an increased risk of severe side effects leading to hospital care (1.56 (1.14–2.12)). While mRNA vaccines were associated with a higher incidence of any side effect (1.06 (1.01–1.11)) compared with viral vector-based vaccines, these were generally milder (p < 0.001), mostly local reactions. Importantly, mRNA vaccine recipients reported a considerably lower incidence of systemic reactions (RR < 0.6) including anaphylaxis, swelling, flu-like illness, breathlessness and fatigue and of side effects requiring hospital care (0.42 (0.31–0.58)). Our study confirms the findings of recent randomised controlled trials (RCTs) demonstrating that COVID-19 vaccines are generally safe with limited severe side effects. For the first time, our study links prior COVID-19 illness with an increased incidence of vaccination side effects and demonstrates that mRNA vaccines cause milder, less frequent systemic side effects but more local reactions.
format Online
Article
Text
id pubmed-8002738
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80027382021-03-28 Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey Mathioudakis, Alexander G. Ghrew, Murad Ustianowski, Andrew Ahmad, Shazaad Borrow, Ray Papavasileiou, Lida Pieretta Petrakis, Dimitrios Bakerly, Nawar Diar Life (Basel) Brief Report An online survey was conducted to compare the safety, tolerability and reactogenicity of available COVID-19 vaccines in different recipient groups. This survey was launched in February 2021 and ran for 11 days. Recipients of a first COVID-19 vaccine dose ≥7 days prior to survey completion were eligible. The incidence and severity of vaccination side effects were assessed. The survey was completed by 2002 respondents of whom 26.6% had a prior COVID-19 infection. A prior COVID-19 infection was associated with an increased risk of any side effect (risk ratio 1.08, 95% confidence intervals (1.05–1.11)), fever (2.24 (1.86–2.70)), breathlessness (2.05 (1.28–3.29)), flu-like illness (1.78 (1.51–2.10)), fatigue (1.34 (1.20–1.49)) and local reactions (1.10 (1.06–1.15)). It was also associated with an increased risk of severe side effects leading to hospital care (1.56 (1.14–2.12)). While mRNA vaccines were associated with a higher incidence of any side effect (1.06 (1.01–1.11)) compared with viral vector-based vaccines, these were generally milder (p < 0.001), mostly local reactions. Importantly, mRNA vaccine recipients reported a considerably lower incidence of systemic reactions (RR < 0.6) including anaphylaxis, swelling, flu-like illness, breathlessness and fatigue and of side effects requiring hospital care (0.42 (0.31–0.58)). Our study confirms the findings of recent randomised controlled trials (RCTs) demonstrating that COVID-19 vaccines are generally safe with limited severe side effects. For the first time, our study links prior COVID-19 illness with an increased incidence of vaccination side effects and demonstrates that mRNA vaccines cause milder, less frequent systemic side effects but more local reactions. MDPI 2021-03-17 /pmc/articles/PMC8002738/ /pubmed/33803014 http://dx.doi.org/10.3390/life11030249 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Brief Report
Mathioudakis, Alexander G.
Ghrew, Murad
Ustianowski, Andrew
Ahmad, Shazaad
Borrow, Ray
Papavasileiou, Lida Pieretta
Petrakis, Dimitrios
Bakerly, Nawar Diar
Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
title Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
title_full Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
title_fullStr Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
title_full_unstemmed Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
title_short Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
title_sort self-reported real-world safety and reactogenicity of covid-19 vaccines: a vaccine recipient survey
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002738/
https://www.ncbi.nlm.nih.gov/pubmed/33803014
http://dx.doi.org/10.3390/life11030249
work_keys_str_mv AT mathioudakisalexanderg selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey
AT ghrewmurad selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey
AT ustianowskiandrew selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey
AT ahmadshazaad selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey
AT borrowray selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey
AT papavasileioulidapieretta selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey
AT petrakisdimitrios selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey
AT bakerlynawardiar selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey